Office of Research
Clinical Trials

Imaging Voice After Laryngectomy

Adults who have had their voice box removed and use a voice prosthesis may join during a regular clinic visit. A special camera is added briefly to the routine exam to record how tissues vibrate to create voice. The study does not change care and offers no direct benefit.

Tracking Outcomes in People with Heart and Blood Vessel Conditions

This study collects medical information and blood samples from adults treated for serious heart and blood vessel problems. The goal is to better understand how these conditions affect health and recovery. Researchers will use information from regular medical care and may ask some participants to give blood samples during their hospital stay and possibly again after going home. They may also contact participants up to a year after leaving the hospital to see how they are doing. This study does not test any new treatment. It simply gathers information that may help doctors care for future patients with similar conditions.

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA SCC of the Head and Neck

This is a phase II study evaluating the disease-free survival (DFS) of patients with stage III-IV squamous cell carcinoma of the head and neck (SCCHN) and disruptive p53 mutations after primary surgical resection followed by postoperative radiotherapy (PORT) alone or PORT with concurrent cisplatin. Participants in Arm A will undergo IMRT 5 days a week for 6 weeks, and those in Arm B will receive the same RT plus weekly Cisplatin via IV.

This study may be appropriate for those with: Newly Diagnosed Cancer

Brain and spine imaging before and after neck surgery for instability

This research study is looking at how advanced MRI scans can show changes in the brainstem and upper spine in people with craniocervical instability or a condition called basilar invagination. Participants will have MRI scans before surgery and again after surgery as part of their regular care, with one additional special scan. Researchers will compare these images to see how the spine and brainstem change after treatment and whether these changes relate to symptoms and recovery. The goal is to improve how doctors measure treatment success and better understand which patients may benefit from surgery.

QDOT PAS study

This study is a real-world follow-up of people with symptomatic, drug-refractory paroxysmal atrial fibrillation who were treated with the commercially available QDOT MICRO system together with the VISITAG SURPOINT module. It is a non-randomized, observational sub-study of the REAL AF registry. Eligible patients (either enrolled prospectively or added retrospectively if they meet criteria) will have their treatment and outcomes tracked. Safety is checked from the procedure through the first 7 days after ablation. Effectiveness is measured by whether participants remain free of atrial arrhythmia at 12, 24, and 36 months after the procedure. Participants must be adults who can give consent and can complete follow-up visits. The study does not change clinical care; it records outcomes and any adverse events after standard-of-care treatment with the QDOT MICRO system and VISITAG SURPOINT.

Pasritamig With Docetaxel Study

This phase 3 trial tests whether adding pasritamig to standard chemotherapy (docetaxel) helps men with metastatic castration resistant prostate cancer live longer without their disease getting worse on scans. Eligible men must have prostate adenocarcinoma that has spread, be on hormone lowering treatment or surgically castrated, have had at least one prior androgen receptor targeted therapy, and be in generally good health for cancer treatment. Participants are randomly assigned to receive pasritamig plus docetaxel or docetaxel alone. Doctors will use imaging scans to track when the cancer progresses, and will also measure overall survival, pain and quality of life, PSA blood changes, need for more treatment, bone related problems, tumor response if measurable, and side effects. Blood tests, scans, and questionnaires are used during treatment and for follow up. The main question is whether the combination delays radiographic progression compared with chemotherapy alone.

This study may be appropriate for those with: Metastatic Cancer

Study of CDK4/6 Inhibitor Dosing in Older Metastatic Breast Cancer Patients

This study seeks to help older patients (65 years and above) with metastatic breast cancer by testing different dosing strategies for CDK4/6 inhibitors. It aims to determine if starting these medications at a lower dose and increasing as tolerated could help patients manage side effects better, enabling them to continue their treatment longer. Participants can choose between the drugs palbociclib or ribociclib and an endocrine therapy, with dosing randomly assigned to either start at full dose (common practice) or begin at a lower dose and increase if tolerated. The trial will track the length of time patients stay on their medication, the side effects experienced, and overall survival and quality of life.

This study may be appropriate for those with: Metastatic Cancer

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations. Participants will choose to undergo surgery to remove the fallopian tubes only and plan to have the ovaries removed in the future (BLS group) or remove the fallopian tubes and ovaries at the same time (BSO group).

This study may be appropriate for those with: Newly Diagnosed Cancer

Measuring Tongue Strength and Swallowing

Adults having a routine swallow x-ray can join a brief tongue strength test to see how tongue function relates to swallowing.

Comparing Two Biceps Tenodesis Techniques to Understand Recovery and Shoulder Function

This study compares two common ways of performing biceps tenodesis, a surgery used to treat shoulder pain caused by problems with the biceps tendon. One method, done by Dr. Grawe, uses an arthroscope and repairs the tendon above the pectoral muscle (arthroscopic supra‑pectoral). The other method, used by Dr. Utz, Dr. Summers, and Dr. Branam, uses an open incision below the muscle (open sub‑pectoral). Both are standard procedures used widely in shoulder surgery. Adults who are advised to undergo biceps tenodesis may be invited to participate. After agreeing to join the study, patients will complete short questionnaires about shoulder function and general health, and their shoulder motion will be measured. The type of surgery they receive will be based on the surgeon performing the procedure-not by randomization. After surgery, participants return for follow‑up visits at 6 weeks and at 3, 6, 12, and 24 months. At these visits, doctors check healing, shoulder movement, and symptoms. Patients also complete questionnaires to track pain and shoulder function. A routine ultrasound at the 3‑month visit helps evaluate how the tendon is healing. The study also includes a scar assessment to understand patient satisfaction with the appearance of their incision. The purpose of the study is to learn whether one surgical technique leads to better recovery, improved strength, less pain, or better cosmetic results. Both surgeries are standard treatments and pose no additional risks or costs beyond normal care. The information learned will help guide future patients and surgeons in choosing the most effective approach for biceps tendon problems.

Use of a new medication for prevention of fetal/neonatal thrombocytopenia (low platelets)

Fetal neonatal alloimmune thrombocytopenia (fNAIT) is a rare disease in pregnancy in which women develop antibodies against proteins on platelets (the cells in our blood that are help with clotting). These antibodies can cross the placenta in pregnancy and, if the fetus has that protein on his/her platelets, they can cause destruction of these cells. This results in thrombocytopenia (low platelets) and can lead to severe bleeding events. Standard prevention of disease in pregnancy includes immune suppression with something called IVIG and prednisone. We are comparing this treatment to a novel treatment using a medication called nipocalimab, a treatment that aims to block transfer of the antibodies across the placenta. Patients will be randomly assigned to receive either nipocalimab or the IVIG+Prednisone, and we will monitor the safety and response in the fetus and baby.

LTI03 Phase 2 IPF Study

This study tests LTI-03, an experimental inhaled medicine, in people with idiopathic pulmonary fibrosis (IPF). The drug is given as powder capsules that participants inhale using a device. About 120 people with IPF diagnosed within the past 5 years will be randomly assigned to low or high dose LTI-03 or matching placebo and neither they nor the study staff will know which they receive. The study includes a 28-day screening period, 24 weeks of treatment, and a 4-week follow-up. Participants will make up to nine clinic visits for safety checks, breathing tests, blood samples, symptom questionnaires, and lung scans at the start and end of treatment. The study will look at side effects and whether LTI-03 affects lung scarring, lung function, and symptoms compared with placebo.

Vedolizumab and Tofacitinib in UC

This open-label, single-group study will enroll about 65 adults with moderate to severe ulcerative colitis who have not successfully treated their disease with 1-2 prior TNF blocker drugs. All participants receive a combination of vedolizumab (300 mg IV) and tofacitinib (10 mg oral) for 8 weeks. Those who show a clinical response at Week 8 will stop tofacitinib and continue vedolizumab alone for 44 more weeks. The study aims to see how many people reach clinical remission early (Week 8) and maintain remission up to Week 52, and to collect safety and quality-of-life information. Participants are followed for safety for at least 26 weeks after their last dose. The study includes assessments of symptoms, endoscopy, laboratory markers, quality-of-life questionnaires, and monitoring for side effects.

Study on Safety of Treprostinil for Pulmonary Hypertension

This study is testing a drug called LIQ861, which is inhaled as a dry powder, to see if it is safe for patients with certain kinds of pulmonary hypertension (PH), specifically WHO Group 3 PH and ILD. The main goal is to check the safety and tolerability of the drug, while secondary goals include examining patients' exercise ability and other health markers. Around 60 people with PH related to lung diseases are expected to join the study. To be eligible, participants must be able to walk a certain distance and have stable medication. People with certain heart conditions or recent infections cannot participate.

Youth Weight Gain OLZ SAM vs Olanzapine

This is a 52-week, randomized, double-blind study in children and teens with schizophrenia or bipolar I disorder. Participants will get either OLZ/SAM (olanzapine combined with samidorphan) or olanzapine alone. The main goal is to compare weight change using BMI Z-score at 12 weeks. The study also looks at how many kids have a meaningful BMI Z-score increase, waist size, symptom scores for schizophrenia or bipolar disorder, time until they stop the study drug, and any side effects up to 52 weeks. Eligible participants are aged 13-17 for schizophrenia or 10-17 for bipolar I, are outpatient-capable, have caregiver support, and are either on olanzapine now or had a poor response to another antipsychotic. People are not allowed in the study for reasons such as certain other psychiatric or neurologic problems, recent opioid use, recent olanzapine exposure or poor response, extreme BMI, diabetes or recent changes in weight programs. Safety and symptoms will be checked regularly during the study.

GS 0415 in People With HIV Study

This is a Phase 1b study testing an investigational drug called GS-0415 in adults with HIV whose virus is already well controlled on HIV medicines. The study will test increasing single doses (single ascending dose, SAD) and increasing multiple doses (multiple ascending dose, MAD) given either under the skin (subcutaneous) or into a vein (intravenous). Some participants will get the drug and others will get placebo; the study is single-blind so participants do not know which they receive. The main goals are to check safety, tolerability, and how the body handles the drug (how much is in the blood over time). People must be 18–65, on stable HIV treatment for at least a year, have suppressed viral load, and meet basic weight and health rules. The study will monitor side effects, lab tests, immune measures, drug levels in blood, and whether participants make antibodies against GS-0415. Participation lasts up to about 99 days depending on the dose group.

APS Phenotyping Study

This is a prospective observational study of adults hospitalized with or at risk for ARDS, sepsis, or pneumonia. Participants give clinical information, answer questionnaires, and provide biological samples (blood, urine, stool). If on a ventilator, respiratory samples are collected. Data and samples are gathered while in the hospital and again after discharge at 3, 6, and 12 months. The study aims to sort patients into biologic subgroups (phenotypes), find measurable markers tied to those groups, understand illness severity and recovery, and build a biobank for future research into causes and new treatments. There is no experimental drug or therapy in this study; it focuses on observation, testing, and sample collection to improve understanding of these critical illnesses.

Study on Alzheimer's Disease Risk in Adults with Down Syndrome

This study aims to form a trial-ready group of adults with Down Syndrome (DS). It includes 120 healthy participants aged 25-55. Researchers will conduct cognitive and clinical tests to analyze relationships between brain markers and cognitive abilities. The goal is to improve future Alzheimer's clinical trials, focusing on disease patterns specific to people with DS. Participants will share data with another ongoing study for more comprehensive research outcomes.

Studying Swallowing With Ultrasound

Adults with normal or swallowing problems will have ultrasound imaging during swallowing tasks to better understand how the tongue and throat move. This may improve future swallowing evaluations.

Comparing Two Surgical Methods to Help Tibia Fractures Heal: Internal Compression vs Backslapping

This study is comparing two common ways surgeons help a broken shinbone (tibia) heal after placing a metal rod inside the bone. One method uses a technique called "backslapping" that allows small movements at the screw holes (dynamic locking). The other method uses the rod to gently squeeze the fracture together (internal compression) and then holds it firmly (static locking). Both methods are standard and use approved implants. Adults with a straight‑across tibia fracture may qualify. Participants are randomly assigned to one of the two methods. Everyone may put full weight on the leg right after surgery unless the treating team advises otherwise for safety. Patients return for checkups with X‑rays at around 6, 12, 24, and 52 weeks so the team can measure healing and any complications. The study's main goal is to learn which method leads to faster and more reliable bone healing and to understand any differences in risks like implant breakage, infection, or the need for additional procedures. What we learn may help future patients and surgeons choose the approach that offers the best chance of strong, timely healing.

Blood Test for ctDNA in Guiding Immunotherapy After Bladder Cancer Surgery

This study investigates whether a blood test can detect leftover cancer after bladder surgery and guide further treatment using immunotherapy. It aims to identify patients who might need additional treatment to prevent cancer from coming back. The study uses blood tests to look for circulating tumor DNA (ctDNA), which can indicate cancer presence. Patients testing positive for ctDNA might receive immunotherapy drugs nivolumab and relatlimab, while those who test negative might not get additional treatment immediately. This research hopes to improve survival rates and quality of life for bladder cancer patients by tailoring immunotherapy based on ctDNA results.

This study may be appropriate for those with: Newly Diagnosed Cancer

DISP 10 Advanced GI Cancer Study

This is an early phase (Phase 1) study testing DISP 10, a combination of an engineered adenovirus (DV-10) and a CAR T cell therapy (idecabtagene vicleucel or ide‑cel). Adults with advanced or metastatic cancers of the esophagus, gastroesophageal junction, stomach, or colon who have measurable disease and at least one site for biopsy may join. The study has two parts: Part 1 slowly increases doses to find a recommended dose for expansion, focusing on safety and dose‑limiting toxicities. Part 2 treats more participants at that dose to learn about safety and whether tumors shrink or stabilize. Main goals are to record side effects, establish a safe dose, and measure tumor response. Participants must have good organ function and no major infections, recent transplants, or prior similar viral or CAR T therapies. Follow up includes frequent checks after treatment and ongoing monitoring for up to 2 years, with long term survival follow up possible up to 15 years.

This study may be appropriate for those with: Metastatic Cancer

Testing a New Combination Therapy for Advanced Lung Cancer

This study is looking at a new treatment combination for people with advanced lung cancer who have stopped responding to typical immune checkpoint inhibitors. The new combination includes the drugs N-803, tislelizumab, and docetaxel vs. just docetaxel alone, to see which is more effective in extending patients' lives. Adults 18 or older with this specific type of cancer could participate if they meet certain health requirements. Key aspects include the ability to follow the study procedures, managing contraception requirements, and having a specific level of health for various bodily functions. Some individuals will not qualify if they have recent treatments that conflict with the new drugs, have severe allergies to study drugs, or other significant health concerns.

This study may be appropriate for those with: Metastatic Cancer

ZEN003694 with Capecitabine for Advanced Solid Tumors

This phase I trial evaluates the safety, side effects, and optimal dosage of ZEN003694 combined with standard treatment capecitabine in patients with metastatic or unresectable solid tumors that have worsened after standard therapy. ZEN003694, a BET protein inhibitor, could inhibit tumor growth by targeting cells that produce excessive BET proteins. Capecitabine, an antimetabolite, converts into fluorouracil inside cancer cells to destroy them. The combination of ZEN003694 and capecitabine aims to safely treat these advanced cancers.

This study may be appropriate for those with: Metastatic Cancer

Evaluating Pegozafermin for Treating Liver Disease

This study is looking at how safe and effective a medication called pegozafermin is for people with liver disease called MASH, which involves an advanced form of 'fatty liver' known as cirrhosis. Participants in this study have a specific stage of liver damage known as stage F4 MASH. The study will help researchers understand if pegozafermin can improve liver health by looking at changes in liver fibrosis, a condition that causes the liver to become scarred. The study takes place over several years and involves regular testing including liver biopsies at the start and after two years to see if the liver disease has improved by one stage or more. It also looks at how the treatment affects liver functions over a longer period of up to five years.

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

This is a randomized trial for patients diagnosed with Esophageal Cancer comparing Proton Beam Therapy and Intensity Modified Photon Radiotherapy. Patients randomized to Arm 1 will undergo Proton Beam therapy with concurrent weekly chemo with paclitaxel/carboplatin. Patients in Arm 2 will undergo IMRT with concurrent paclitaxel/carboplatin. The primary endpoint of this study is Overall Survival.

This study may be appropriate for those with: Newly Diagnosed Cancer

Teclistamab Maintenance Study

This is a Phase 3 clinical trial for people with newly diagnosed multiple myeloma who have completed initial therapy and are starting maintenance treatment after autologous stem cell transplant. Participants are randomly assigned to one of three maintenance options: teclistamab plus lenalidomide, teclistamab alone, or lenalidomide alone. The study will compare how long people live without their disease getting worse (progression-free survival) and how many achieve a deep response with no detectable disease at 12 months. Participants will be followed during treatment and for long-term outcomes, including overall survival, quality of life, and safety, for up to about 8 years. The goal is to find whether teclistamab, by itself or with lenalidomide, gives better and longer-lasting control of myeloma than standard lenalidomide alone.

This study may be appropriate for those with: Newly Diagnosed Cancer

Genetics Guided Escitalopram Study

This study will enroll about 132 teens ages 12-17 who have generalized, social, and/or separation anxiety. For 12 weeks, participants are randomly assigned to one of two ways of giving the antidepressant escitalopram: standard dosing or dosing guided by a genetic test that predicts how they process the drug. The goal is to see whether using genetic information leads to better anxiety relief and fewer side effects, especially activation (increased restlessness or irritability). The study compares changes in anxiety scores over 12 weeks and monitors safety and activation. Caregivers help with safety checks and medicine monitoring. The study includes a screening visit, a baseline visit, and regular follow-up visits during the 12-week treatment period.

How eating a meal affects tongue strength and fatigue

This study is exploring how eating a normal meal may cause tongue fatigue and whether this differs by age. Healthy younger and older adults will complete simple tongue strength tasks before and after eating a standardized meal. These tasks help researchers understand how eating affects the muscles used for chewing and swallowing. Participation involves a single visit and does not change medical care. The results may help improve understanding of fatigue related to eating as people age.

Efficacy and Safety of Iptacopan for IC-MPGN

This study is investigating iptacopan's effectiveness and safety for treating idiopathic immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). People aged 12-60 with IC-MPGN who are already on stable treatment may participate. The study will compare iptacopan with a placebo in terms of reducing protein levels in the urine and improving kidney function (measured by eGFR). It also assesses whether patients feel less fatigued. After completing the study, participants can choose to continue iptacopan in another study. The study involves safety monitoring, includes vaccinations for certain infections, and is open only to those meeting specific health criteria without certain exclusions.

Adding SNDX-5613 to the Standard Chemotherapy Treatment for Newly Diagnosed Patients With Acute Myeloid Leukemia

A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged Disease. This phase Ib trial evaluates the safety, side effects, and optimal dosage of SNDX-5613 in combination with standard chemotherapy (daunorubicin and cytarabine) for patients with newly diagnosed acute myeloid leukemia (AML) harboring NPM1 or MLL/KMT2A gene mutations. SNDX-5613 inhibits specific intracellular signaling pathways essential for the survival of cancer cells. Chemotherapy agents like daunorubicin and cytarabine work by various mechanisms to halt cancer cell proliferation, either by directly killing the cells, preventing their division, or inhibiting their spread. The hypothesis is that adding SNDX-5613 to conventional chemotherapy could potentially enhance cancer control, leading to longer periods of remission or stabilization compared to chemotherapy alone.

This study may be appropriate for those with: Newly Diagnosed Cancer

Comparing Surgical vs Nonsurgical Care for Fragility Pelvic Fractures: The FLIPER Pilot Study

Fragility fractures of the pelvis are increasing as the population ages. Doctors often treat these injuries either with surgery or with nonsurgical care focused on early movement and rehabilitation. It is not yet clear which option works best for which patients, and previous studies have had limitations. The FLIPER pilot study is designed to prepare for a larger, more definitive study by testing whether it's practical to compare these treatments fairly and safely. People aged 60 and older with a specific type of low‑energy pelvic fracture (LC1) may be eligible. After consent, the research team collects information from the hospital chart and from the patient or a family member. The care team decides whether surgery or nonsurgical care is best, based on their usual clinical judgment. About four months after the injury, participants (or their caregivers) are contacted to see how they are doing. The study focuses on three important outcomes at about four months: Survival (whether the patient is still living), Ability to walk across a room, and "Days at home," meaning the number of days not spent in a hospital or facility. The team will also ask patients and surgeons if they would be willing to take part in a future randomized study that directly compares surgery to nonsurgical care. This helps researchers learn whether a larger trial would be acceptable and realistic. No experimental treatments are involved. All care decisions are made by the medical team as part of normal practice. The information learned from this pilot will guide the design of a larger study to improve treatment decisions and outcomes for older adults with fragility pelvic fractures.

KarXT for Bipolar I Mania

This is a Phase 3, randomized, double-blind, placebo-controlled inpatient study testing KarXT for adults hospitalized with an acute manic episode of Bipolar I disorder (including mixed features). The main goal is to see if KarXT reduces mania symptoms more than placebo over a 3-week treatment period, measured by change in the Young Mania Rating Scale (YMRS) and clinician global ratings. Participants must be hospitalized for the episode, meet minimum severity scores, and stop other psychotropic drugs before starting. People with other main psychiatric disorders, recent substance use disorders, high suicide risk, or significant liver disease are excluded. The total time in the study, including screening and a safety follow-up, is up to 7 weeks.

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

The purpose of this research is to study if a decrease in the dose of radiation to regions which have no visible cancer will be as effective as the standard dose. The dose to all visible cancer remains unchanged to the standard radiation approach. The researchers believe that a lower dose could be just as helpful for treating your cancer, while reducing the side effects of radiation and improving quality of life. The current standard care treatment for OPSCC can have debilitating side effects. The researchers believe that using a decreased dose of 30 Gy from 46-54 Gy to regions without visible cancer but which have a risk of microscopic cancer might be just as effective for treating your cancer with less side effects. The combination of these approaches is not considered the current standard of care and will be considered research. You will continue to receive standard systemic therapy of cisplatin during your radiation therapy.

This study may be appropriate for those with: Newly Diagnosed Cancer

TRACK TBI Precision Medicine Part 3

This is a randomized phase 2 trial testing an FDA approved drug given off label to adults with moderate to severe traumatic brain injury (TBI). Participants who are treated within 24 hours of injury are randomly assigned to receive the study drug or a placebo. The main goal is to see if the drug improves short term functional outcome measured at 4 weeks. The study also looks at blood markers of brain injury, standardized tests of consciousness, brain MRI measures, longer term function and cognition, quality of life, and caregiver burden up to six months after injury. Enrollment is by invitation and a legally authorized representative provides consent when the patient cannot. Participants must be able to undergo MRI and meet study blood test criteria. Certain medical conditions such as severe other injuries, kidney or liver disease, active infections, pregnancy, or inability to follow up will disqualify a person from participation.

Study on UB-VV111 and Rapamycin for CD19+ B-cell Malignancies

This Phase 1 research involves the new drug UB-VV111, tested with or without another drug called Rapamycin, in people with specific B-cell cancers that have returned or don't respond to existing treatments. The goal is to understand if these treatments are safe and how well they work against cancer. Participants need to meet certain criteria, such as being 18 years or older, having specific types of relapsed or refractory B-cell lymphomas or leukemia, having no serious uncontrolled health conditions, and having good organ function. People can't participate if they are pregnant, have certain infections, or are part of another trial. Expected outcomes are monitored over a two-year timeframe.

This study may be appropriate for those with: Relapsed / Refractory Cancer

DECADE-Brain Health study

Intracerebral hemorrhage (ICH) is the most extreme subtype along the spectrum of CSVD that includes white matter hyperintensity (WMH), small vessel (lacunar) ischemic stroke and vascular cognitive impairment. We propose to re-enroll 400 (275 non-Hispanic European descent and 125 African-descent) participants of i3C DECADE study, (MPI: Bazzano, Urbina and Carmichael) which is following biracial cohorts in the Cincinnati, Ohio regions originally recruited as children in the 1970s and 1980s, for a 3-year (+/- 6 months) follow-up MRI, additional serial cognitive examinations and detailed dietary histories which will include a polyamine specific history and serial blood sampling. The proposal will copy the i3C DECADE exam including an identical MRI protocol and use the same recruitment and retention tools.

Phase II Trial of Asciminib, Prednisone, Blinatumomab, for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia

This phase II study tests whether adding asciminib to a treatment plan of dasatinib, prednisone, and blinatumomab helps adults newly diagnosed with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Treatment has three parts: an induction phase to try to put the leukemia into remission, a post-remission consolidation phase with repeated 42-day cycles, and a maintenance phase where patients take oral drugs for up to five years if they benefit. Doctors will check response by measuring BCR-ABL levels in blood/marrow and by flow cytometry for measurable residual disease. Main goals are to see how many people reach a major molecular remission by about day 85 and to track remission rates, survival, and side effects over time. The study also collects samples to study genetic changes linked to response or resistance.

This study may be appropriate for those with: Newly Diagnosed Cancer

Child and Teen Bipolar Network

This study follows about 80 youth ages 9-19 who have bipolar spectrum disorders or cyclothymic disorder. After a screening and baseline visit (which includes a diagnostic interview and a blood draw to measure inflammation), families take part in regular follow-up for 12 months. Parents complete weekly online ratings of their child's symptoms. The study team tracks the youth's medications and any psychosocial therapies they receive as part of usual care. Major visits include baseline/intake and repeat assessments at 6 and 12 months, using standard questionnaires about mood, behavior, family conflict, quality of life, anxiety, and substance use. The goals are to improve early and accurate diagnosis, learn which signs predict better or worse outcomes (focusing on mood instability and C-reactive protein), and develop standardized tools and procedures that clinics can use to treat youth with or at risk for bipolar disorder.

IkT001Pro Pulmonary Arterial Hypertension

This was a Phase 2, randomized, double-blind, placebo-controlled trial testing two dose levels of an experimental drug called IkT-001Pro in people with pulmonary arterial hypertension (PAH). About 150 people were planned to join at multiple global sites. The study had two parts: a 26-week blinded treatment period comparing 300 mg and 500 mg doses against placebo, followed by a long-term 36-month extension where participants could continue on a study dose. The main goals were to measure the drug�s effect on the resistance in lung blood vessels and to evaluate safety and tolerability. Other goals included measuring walking distance, symptoms, clinical worsening events, quality of life, and drug levels in the body. Participants needed a confirmed diagnosis of PAH, be symptomatic (WHO class II or III), be on stable PAH therapy, and meet walking test criteria. The study was withdrawn and did not complete enrollment.

Efficacy and Safety of Adjuvant in Patients With Resected Pancreatic Ductal Adenocarcinoma

This study is evaluating an experimental drug called autogene cevumeran in patients with pancreatic ductal adenocarcinoma that has been resected (surgically removed). The goal is to find out whether combining these newer therapies (atezolizumab and autogene cevumeran) with standard chemotherapy is safe and more effective at reducing the risk of cancer returning compared to chemotherapy alone.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

This study may be appropriate for those with: Newly Diagnosed Cancer

LAAOS - 4

This multicenter, open-label, randomized controlled trial evaluates whether catheter-based endovascular closure of the left atrial appendage (LAA) reduces ischemic stroke or systemic embolism in patients with atrial fibrillation who remain at high stroke risk despite treatment with oral anticoagulants. Eligible participants have persistent or permanent AF, or paroxysmal AF with prior stroke, a CHA2DS2-VASc score ≥4, and have been on oral anticoagulation for at least 90 days before enrollment. Participants are randomized to receive LAA occlusion using devices such as the WATCHMAN in addition to standard care versus continued medical therapy. Endpoints are assessed by blinded adjudicators, and participants are followed until a total of 265 primary efficacy events have occurred (estimated average follow-up about 4 years). The primary outcome is prevention of ischemic stroke or systemic embolism; safety outcomes include procedural complications, bleeding, and device-related events.

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/​11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 Tablet and Food Effect Pharmacokinetic (PK) Substudy will assess the PK profile of IDE196 tablet and evaluate the effects of food on the PK profile of IDE196 tablet Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.

This study may be appropriate for those with: Metastatic Cancer

Studying TRX319 Cell Therapy for Progressive Multiple Sclerosis

This research study is testing an investigational cell therapy called TRX319 for adults with primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS). The goal is to learn whether TRX319 is safe and to look for signs that it may help slow or improve disease progression. Participants will receive a single intravenous infusion of TRX319. Some participants may also receive bendamustine before the infusion, depending on the study group. The study includes screening tests, physical examinations, blood tests, MRI scans, spinal fluid testing, and assessments of walking, hand function, vision, and thinking abilities. Participants will be followed for about one year after treatment. Information from this study may help researchers develop new treatment options for people with progressive forms of multiple sclerosis.

Safety and Effectiveness of PYX-201 in Solid Tumors

This study is testing a new drug called PYX-201 in adults with advanced solid tumors that have not responded to usual treatments or for whom there are no suitable treatment options. The goal is to find out what dose of the drug is safe and can be tolerated well. Researchers will monitor participants to see how their bodies react to the drug, including any side effects and how the drug moves through their system. Participants must be adults with certain cancers, such as breast, lung, or ovarian cancer, who meet health criteria like having normal kidney and liver function. The study aims to explore both the safety and preliminary effectiveness of PYX-201 over approximately 3 years. It is open-label, meaning all participants receive the drug, and no placebo is involved. Measurements will focus on potential toxicities and adverse events as well as biological markers from blood samples. Participants must not have severe infections or other active cancers. The research hopes to pave the way for further clinical development if results are promising.

This study may be appropriate for those with: Recurrent Cancer

AI Tool for Airway Anatomy

Adults will have brief ultrasound scans of the neck to help train a computer system to recognize airway structures, which may aid future emergency care.

Acupuncture for Sickle Cell Pain

This research tests whether acupuncture can reduce pain in people with sickle cell disease and how it affects the brain and blood markers. Participants 14–80 years old who have chronic sickle cell pain are randomly assigned to receive ten sessions (30 minutes each) of either traditional needle acupuncture or non-needle laser acupuncture. The main treatment period includes about 14 in-person visits over roughly 6–8 weeks. Investigators will collect pain and health questionnaires, perform sensory testing before and after treatments, and record brain activity using MRI, fNIRS, and EEG. During imaging, controlled pain stimuli will be applied to the lower leg. Blood samples will be taken before and after the treatment course to study biomarkers, and a noninvasive inner-eyelid image will be used to estimate hemoglobin. Participants will be followed monthly for up to 12 months after the in-person visits to track pain and quality of life. Some procedural details are not provided now to preserve study integrity.

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

The main purpose of this study is to measure the safety and effectiveness with ivonescimab/SMT112 in combination with chemotherapy drugs, i.e., FOLFOX (Oxaliplatin, Leucovorin and Fluorouracil) in the first-line treatment of metastatic colorectal cancer (mCRC) compared to bevacizumab in combination with chemotherapy drugs, i.e., FOLFOX (Oxaliplatin, Leucovorin and 5-Fluorouracil). Ivonescimab/SMT112 is considered investigational and has not been approved by the U.S. Food & Drug Administration/local Regulatory Authority for treatment or sale. Bevacizumab is a different approved drug sold under the brand name Avastin. FOLFOX is a standard chemotherapy regimen made up of the drugs folinic acid (leucovorin, FOL), fluorouracil (5-FU, F), and oxaliplatin (Eloxatin, OX).

This study may be appropriate for those with: Metastatic Cancer

Improving Sleep and Thinking in People with Parkinson Disease Using Different Brain Stimulation Settings

This study is testing whether changing the settings of an implanted brain stimulation device during sleep can improve sleep quality and thinking abilities in people with Parkinson disease. Participants who already have a deep brain stimulation device will receive two different stimulation settings in a random order. One setting uses their usual stimulation day and night, while the other uses a lower setting during sleep. Participants will complete sleep questionnaires, thinking and memory tests, and movement assessments during the study. Researchers hope to learn whether nighttime brain stimulation changes can improve sleep and thinking without worsening movement symptoms.

Letrozole Study in Recurrent High Grade Gliomas

Patients will receive up to 20 mg of letrozole orally each day both before and after surgical resection. The primary endpoint of this study is the measurement of tumoral bioavailability of letrozole.

This study may be appropriate for those with: Recurrent Cancer

Study of JANX007 in Metastatic Castration-Resistant Prostate Cancer

This study is exploring a new treatment called JANX007 for adults with metastatic castration-resistant prostate cancer. It is a Phase 1 trial, which is the first time this drug is being tested in humans. The main goal is to check its safety and find out if it can be tolerated by patients. Scientists will also look at how the body processes the drug and its initial effectiveness in fighting cancer. Participants need to have a type of prostate cancer that didn't respond to other treatments including hormone therapy and chemotherapy. The study will not include people who have had an organ transplant or specific heart problems.

This study may be appropriate for those with: Metastatic Cancer

Bladder Preservation Immunoradiation

This Phase II study tests whether combining the immune drug pembrolizumab with radiation therapy can allow people with muscle invasive bladder cancer to keep their bladder after the tumor has already shrunk from pre-surgery chemotherapy. Eligible patients have an excellent clinical response after neoadjuvant chemotherapy and will receive daily photon radiation to the bladder Monday through Friday for up to about 4 weeks while also getting pembrolizumab through an IV every 3 weeks. Before joining, patients have had a TURBT (a bladder tumor biopsy/removal procedure) and staging scans. The study tracks how long patients keep their bladder without cancer returning, whether they later need bladder removal (salvage cystectomy), survival outcomes, side effects, and patient-reported symptoms. Blood, urine, and tissue samples will be stored for future research. After finishing treatment, participants are followed regularly for up to 5 years.

This study may be appropriate for those with: Newly Diagnosed Cancer

Dose Escalation/​Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 alone or with Pembrolizumab

This clinical trial is assessing a new treatment, called TEV-56278, which is being tested alone and in combination with another drug called Pembrolizumab. This trial focuses on individuals who have advanced solid tumors. These types of tumors might be resistant to standard treatments or have not responded well to them. This study, conducted by Teva Branded Pharmaceutical Products, aims to find a safe and effective dosage of TEV-56278. It hopes to determine whether it can effectively inhibit tumor growth when used on its own or together with Pembrolizumab. Participants will be observed for any side effects and to see how well the tumor responds to the treatment. The study duration includes being treated for up to one year and followed for up to another year, totaling a possible two years per participant. The trial is ongoing, offering treatment possibilities for those who meet specific inclusion criteria, including having previously received treatment for their tumor and having a life expectancy of at least 12 weeks.

This study may be appropriate for those with: Metastatic Cancer

New Surgical Tool for Brain and Skull Base Surgery

This research is studying a surgical tool called DuraStat that is used to help close the protective lining around the brain during certain skull base surgeries done through the nose. Sometimes this lining is opened during surgery and needs to be carefully repaired to prevent fluid leaks or infection. The study will follow adults who are already having this type of surgery and need a repair during the procedure. Doctors will look at how well the repair works and how patients heal over time. Follow-up visits are part of normal surgical care, and participation does not require extra procedures beyond standard treatment.

Study on IOV-4001 for Advanced Melanoma and NSCLC

This study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).

This study may be appropriate for those with: Metastatic Cancer

SPARX3

This study is a Phase III multi-site, randomized, evaluator-masked, study of endurance exercise on 12 month, 18 month, and 24 month changes in the MDS-UPDRS Part III score. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax and 2)80-85% HRmax 4 times per week. Secondary aims will test hypotheses related to ambulatory mobility, daily activity, cognition, fitness, quality of life, measures of dopaminergic neuronal integrity and blood-derived biomarkers of inflammation and neurotrophic factors.

Higher Dose Radiation Therapy for Advanced Pancreatic Cancer Trial

This study is exploring if giving higher doses of radiation can help people with advanced pancreatic cancer live longer. Participants must have already undergone 4-6 months of chemotherapy and have stable disease without progression. There are two groups in the study. One group will receive standard treatment, which could include continuing chemotherapy, a normal dose of radiation, or observation. The other group will receive higher doses of radiation over a shorter period to see if it prolongs their survival. Patients will have regular follow-ups and will be checked through blood tests, imaging scans, and tissue biopsies. They are monitored over a period that includes every three-month checkups for two years and then yearly for another three years. This study aims to not only see if survival improves but examine side effects, quality of life, and any changes in disease progression.

This study may be appropriate for those with: Metastatic Cancer

Monitoring Immune Responses After Kidney Transplant

This research study is focused on people who are receiving a kidney transplant. The goal is to learn more about how the body's immune system responds to a new kidney. By studying blood, urine, and small samples of kidney tissue that are already collected as part of routine care, researchers hope to better understand why some transplanted kidneys work well while others develop problems. People who join the study do not receive a new treatment, but their participation may help improve care for future kidney transplant patients.

Pramipexole vs Escitalopram Study

This is a Phase 2, open-label randomized trial that will compare two medicines for depression in people living with HIV: pramipexole extended release and escitalopram. Participants will be randomly assigned to one of the two treatments and followed for about 24 weeks. Study visits will check how participants are feeling, measure depression and thinking skills, and watch for side effects. A smaller optional sub-study will collect and study spinal fluid in up to 36 people to see how treatment affects brain inflammation markers.

Studying throat growths in adults to help find better treatments

This study looks at growths in the voice box and airway caused by a virus. When adults have planned procedures to treat these growths, a small amount of tissue (and sometimes blood) is collected and used to grow cells in the lab. Researchers study the virus and genes and test different medicines on the lab grown cells to see what works best. There are no extra study visits. Participation continues while a person receives usual care. The main risk is a privacy breach, and steps are taken to protect information. Results are not shared with participants. About 50 adults are expected to take part.

Early Pelvic Floor Therapy Study

This is a small single group study of 28 women with invasive cervical cancer who will get pelvic external beam radiation as part of their treatment. About four weeks after finishing radiation, participants will begin pelvic floor physical therapy. The study will measure how many women have fecal incontinence three months after radiation using a standard patient survey (EORTC QLQ CX24). A survey score of 1 or higher will count as incontinence. The study will also look at urinary incontinence, sexual symptoms, overall quality of life, how well participants follow recommended dilator use, and changes in pelvic floor muscle function (measured with the Brink scale). Assessments will be done before therapy and at three months after radiation. The goal is to see how common bowel leakage is after pelvic radiation and whether early pelvic floor therapy can be studied further as a supportive care approach.

Does latent TB infection raise the risk of diabetes or heart disease?

This research looks at whether having a silent TB infection can increase the chance of developing diabetes or heart problems. Adults with and without latent TB infection will have health checks, blood tests, and simple vessel tests at the start, 6 months, and 24 months. The visit takes about 1-3 hours. The study does not give TB treatment, but test results like cholesterol, A1c, insulin, fasting glucose, and TB blood tests will be shared through the patient portal so people can discuss them with their regular doctor. There may be brief phone check-ins between visits to help with scheduling. There is no direct medical benefit from joining, but what we learn could help improve care for people with a history of TB exposure.

Treprostinil for PH ILD Study

This is a Phase 3 randomized, double blind, placebo controlled study testing an inhaled medicine called treprostinil palmitil inhalation powder (TPIP) in adults who have pulmonary hypertension from fibrotic interstitial lung disease. Participants will take TPIP or a matching placebo once daily for 24 weeks. The main goal is to see if TPIP improves exercise ability measured by the six minute walk test at 24 weeks. The study also looks at clinical worsening events, major illness or death, a blood marker of heart strain (NT proBNP), symptom scores, and blood drug levels. People must have their lung scarring confirmed by CT and pulmonary hypertension confirmed by right heart catheterization. Some heart, lung, clotting, smoking, allergy, or other health problems will prevent participation. Side effects may include cough, throat irritation, headache, flushing, nausea, dizziness and low blood pressure. Results will help show whether daily TPIP is an effective and safe treatment for this group of patients.

PLG0206 to Prevent Knee PJI Recurrence

This study tests whether a single irrigation of the investigational drug PLG0206, given during a DAIR surgery for an infected knee replacement, can reduce infection recurrence and is safe. People who qualify will have the usual DAIR surgery at their hospital. After cleaning the joint, the study drug or a matching placebo will be given as one final wash inside the knee. All participants will receive standard post-operative care, including any antibiotics their doctors order. Participants will be followed for about 12 months to watch for return or persistence of infection, any surgeries needed later, safety problems, knee function, and blood tests. Follow-up includes clinic visits and phone or virtual check-ins at set times over the year. The main goal is to compare how many people in each group have treatment failure (infection return) within 12 months.

Studying the Brains of Elite Athletes

This research study looks at how the brains of elite athletes may be different from others. Participants complete advanced brain scans that measure brain structure and brain activity while resting and performing simple tasks. The goal is to understand how years of intense training may shape the brain and support high-level athletic performance. The study involves one short visit, or two shorter visits, and does not involve treatment or changes to medical care.

VX-147 for APOL1 Proteinuric Kidney

RECRUITING IN JUNE 2024. This is a phase 2/3 adaptive, double-blind, placebo-controlled study with the purpose of evaluating the efficacy, safety, tolerability, and pharmacokinetics (PK) of oral VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease. Phase 2 of the trial is complete as of April 2024 and we will only be recruiting for phase 3.

DLBCL GCB Treatment Study

This is a phase 2 randomized study for people with newly diagnosed germinal center B-cell (GCB) subtype diffuse large B-cell lymphoma (DLBCL). It compares two treatment combinations given with standard chemo (R-CHP): zilovertamab vedotin (MK-2140) plus R-CHP versus polatuzumab vedotin plus R-CHP. The main goal is to see which group has more people with a complete response to treatment at the end of therapy, as measured by imaging reviewed independently. The study also follows participants for progression-free survival, overall survival, event-free survival, how long responses last, side effects, and quality of life measures. People must have PET-positive disease, no prior DLBCL treatment, and certain infections must be controlled to join. Some people are not eligible due to other lymphoma types, serious heart issues, active infections, significant nerve problems, recent other cancers, or recent transplants.

This study may be appropriate for those with: Recurrent Cancer

Cor TRICUSPID ECM Valve Study

This study checks the safety and performance of the Cor TRICUSPID ECM Valve (and a pediatric version) when used to replace a broken or leaking tricuspid heart valve. Adults and children who need surgical tricuspid valve replacement may take part. Before surgery participants have a baseline check, then they get the valve implanted during open heart surgery. Follow-up exams happen at hospital discharge, 30 days, 6 months, 12 months, and then every year up to 5 years. The study will track whether the valve is implanted successfully, whether it works to reduce valve leakage and improve symptoms, and whether there are device‑related complications such as infection, valve failure, or need for another procedure.

Amivantamab Versus Cetuximab in cSCC

This study is testing a new treatment approach for people with cutaneous squamous cell skin cancer that has come back or spread and who have weakened immune systems. Participants are placed into one of two groups. One group gets amivantamab given under the skin together with hyaluronidase to help the drug stay in the body longer. The other group gets cetuximab given into a vein. Treatment is given in 28-day cycles for up to about 24 cycles unless the cancer gets worse or side effects are too severe. Doctors will check safety, how well the cancer responds, and how long people live without cancer growth. Blood tests and scans will be done throughout treatment, and some patients will be followed afterward for years. The study also collects samples for future research.

This study may be appropriate for those with: Metastatic Cancer

Studying Heat Exposure and Pregnancy Health

This research studies how exposure to hot temperatures during pregnancy may affect a mother's body and pregnancy outcomes. Pregnant women at higher risk for early delivery will wear a smart ring that tracks heart rate, sleep, and body temperature, and will have temperature monitors placed in their homes. Participants will also complete short daily and weekly surveys and provide simple samples like blood, saliva, hair, and nasal swabs. The study follows participants for about three months during pregnancy and briefly after delivery. The goal is to better understand how heat affects pregnancy so future steps can be taken to protect mothers and babies.

Self Collection HPV Screening Study

This study tests whether people who collect their own vaginal sample for HPV testing get results that are as accurate as samples collected by a clinician during a pelvic exam. Adults 25 and older who were referred for colposcopy because of an abnormal cervical screening test will first collect a vaginal sample themselves, then have a clinician collect a cervical sample and undergo standard colposcopy with biopsy or other procedures if needed. Lab results are compared to see how well self-collection detects high-risk HPV and signs of cervical precancer or cancer. The study also asks participants about ease of use, comfort, and preferences for self-collection. Results will help guide use of self-collection for cervical cancer screening and possible regulatory decisions.

Finerenone in Kidney Transplants

This study will test a medicine called finerenone in people who have had a kidney transplant. The trial will enroll 150 transplant recipients and will compare finerenone to a placebo in a double-blind, randomized design over about 13 months. The team will check whether it is possible to recruit transplant patients and whether they will accept extra tests like research kidney biopsies and special kidney MRIs. The study will also look at safety and tolerability, especially the risk of high potassium and changes in kidney function. Researchers will measure urine protein, kidney function over time, heart failure events needing care, changes seen on kidney MRI, and changes seen on biopsy tissue in the biopsy subgroup. Results will help decide if larger trials are needed.

Study of PF-07934040 for Advanced Tumors with KRAS Gene Mutations

This clinical study is testing a new cancer medicine called PF-07934040. The study focuses on people with advanced solid tumors, which are cancers that don't go away or stay away after treatment. These tumors have a specific genetic mutation in the KRAS gene, which can make cancer cells grow quickly. The study includes people with types of cancer such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). The study is in Phase 1, meaning it's looking at how safe the medicine is and what effects it has. Researchers also want to find the best dose to give to patients. The medicine can be taken alone or with other cancer treatments. Participants will take PF-07934040 as a pill twice a day in cycles of either 21 or 28 days. Those who are also getting other treatments will have those given by IV at the clinic. The study will last up to four years, with participants visiting the clinic 1 to 4 times every cycle. They can continue the treatment as long as it helps control their cancer. After stopping the medicine (usually around two years), they will be followed for two more years to check on their health. To join the study, participants must have a KRAS gene mutation and show that their cancer has not responded to standard treatments. They must also have a good level of daily functioning and at least one measurable tumor that has not been treated with radiation. There are also specific criteria for different cancer types, such as the number of previous treatments. People cannot join if they have certain health problems, like lung diseases that need steroids, immune system issues, or severe nerve damage. They also can't participate if they've had major surgery or radiation therapy recently, or if they have allergies to the study treatments. The study aims to learn if PF-07934040 is safe and effective in treating these advanced cancers. It will measure safety through any side effects and lab test changes. It will also look at how many participants respond to the treatment, how long it takes for the medicine to reach its peak in the body, and how long it stays there.

This study may be appropriate for those with: Relapsed / Refractory Cancer

TAPUR Study: FDA Approved Drugs Targeting Tumor Gene Abnormalities

The TAPUR Study is focused on understanding how FDA-approved drugs that target specific abnormalities in tumor genes work for patients with advanced cancers. These include solid tumors, multiple myeloma, and non-Hodgkin lymphoma that have a detectable genetic feature that can potentially be treated with these medicines. The study evaluates participants' responses, safety of treatments, survival rates, and helps to form ideas for new clinical trials based on real-world usage of these therapies. Anyone aged 12 or older with certain advanced cancers whose condition can be measured and who meets other criteria may participate. However, those with certain conditions like primary brain tumors or unmeasurable disease may not be eligible.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Cannabidiol for Focal Seizures Study

This is an open-label, single-group study testing a cannabidiol (CBD) oral solution as an extra medicine for people with focal-onset seizures aged 12 to 75. Participants will keep their current anti-seizure medicines (1 to 4 drugs) and add the CBD solution. The main goal is to see whether CBD lowers the number of focal seizures compared to each person's baseline over about 16 weeks. The study will also look at safety, how the body handles the drug (pharmacokinetics), and whether brain imaging (fMRI) or thinking tests predict who responds best. Some people in the study may be early in their treatment and others may have hard-to-treat seizures. The study does not include people with non-epileptic events, recent CBD or cannabis use, certain allergies, or unstable medical or mental-health issues.

Comparing Surgical Options for Treating Recurrent Carpal Tunnel Symptoms After a Prior Release

This study compares three different surgical approaches used when carpal tunnel symptoms return after a previous surgery. Some people experience relief at first, but symptoms later come back, and doctors must decide which type of revision surgery will give the best results. Because there is not enough research comparing these options, this study is designed to help provide clearer answers. Adults who have recurrent carpal tunnel symptoms and have tried nonsurgical treatments such as splinting or injections may qualify to participate. After completing a baseline evaluation, including hand strength testing and questionnaires, participants are randomly assigned to one of three revision procedures. All three techniques are currently used in clinical practice. After surgery, participants will return for follow‑up visits at several points over two years. At each visit they will complete surveys and have simple hand function checks to track improvement in symptoms, comfort, and daily use of the hand. By comparing recovery, hand function, and symptom improvement across different revision procedures, the study aims to help surgeons choose the best option for future patients. The study also looks at whether pre‑surgery symptoms, nerve test results, or imaging findings can help predict how well someone will recover after revision surgery.

Study of Isatuximab, Carfilzomib, and Dexamethasone for Multiple Myeloma

This clinical study focuses on adults with relapsed or refractory multiple myeloma who have had 1 to 3 previous treatments that did not work. The study tests a combination of drugs: isatuximab, carfilzomib, and dexamethasone. The main goal is to see how well this treatment works in fighting the cancer and how the patients respond to it, both physically and emotionally. Participants go through a screening period, followed by up to a year of treatment. They will visit the study location periodically for evaluations. The study measures various outcomes, including overall response rate and possible side effects like infusion reactions. It's important that participants are able to commit to the protocol and fit specific medical criteria while avoiding recent treatments or conditions that might interfere with the study.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Vorasidenib with Temozolomide Trial

This Phase 3 clinical trial tests whether adding vorasidenib to the usual post‑radiation chemotherapy (temozolomide) helps people with newly diagnosed IDH‑mutant grade 3 astrocytoma. Patients are randomly assigned to one of two groups: both get standard radiation followed by temozolomide tablets, and one group also gets vorasidenib tablets while the other gets a placebo. Treatment cycles are 28 days, with the study drug taken daily and temozolomide given on days 1-5 of each cycle, for up to 12 months if the disease does not get worse and side effects are acceptable. Doctors will check tumor status with regular MRI scans and blood tests. The main goal is to see whether adding vorasidenib delays tumor growth (progression‑free survival). The study also looks at safety, overall survival, tumor response, time to next treatment, seizure control, and quality of life. After finishing study drugs, participants are followed for several years to monitor long‑term outcomes.

This study may be appropriate for those with: Newly Diagnosed Cancer

A Multicenter Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated and T474 Gatekeeper Mutant CLL/SLL

This is a phase II research study being conducted at multiple locations. It is designed to test the combination of obinutuzumab and LP‑168 in two groups of people with CLL/SLL: those who have been treated before, and those whose disease has a specific genetic change that makes it harder to treat with standard therapies.Participants will take LP‑168 once a day, starting on the first day of treatment, for up to 12 treatment cycles. About two weeks after finishing the first six cycles, their progress will be checked using blood tests, imaging scans, and a bone marrow sample. After this check‑in, participants will continue taking LP‑168 and will also begin receiving obinutuzumab. Obinutuzumab will be given over six cycles, starting in cycle 7, on several scheduled days early on and then once per cycle through cycle 12. Everyone will receive at least 12 cycles of treatment. At the end of cycle 12, participants will be evaluated again to see how well the treatment worked. This will include blood tests, scans if needed, and examination of blood and bone marrow samples to look for any remaining signs of disease. Participants whose disease is no longer detectable at that point may choose to stop treatment. Those who still have signs of disease will continue taking LP‑168 and will be followed every six months. Additional testing may be done later, and treatment can be stopped if no disease is detected at that time.

This study may be appropriate for those with: Recurrent Cancer

At-Home HPV Screening in the Community

Adults with a cervix can choose to self-test for HPV at a mobile clinic. Education and follow-up support are provided to help prevent cervical cancer.

Riliprubart for Refractory CIDP

This is a Phase 3 clinical trial testing riliprubart, given to adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) whose disease did not respond well to usual treatments (IVIg or steroids). Participants are randomly assigned to receive riliprubart or placebo. The first part (double-blind) compares effects through Week 24 and up to Week 48 for some outcomes. After that, an open-label part allows longer treatment and safety follow-up up to a maximum of 111 weeks. The main goal is to measure how many people have meaningful improvement in disability scores (a drop of at least 1 point on the adjusted INCAT scale) by Week 24 and whether improvements last. The study also checks strength, fatigue, quality of life, side effects, and whether the body makes antibodies to riliprubart. People must meet specific diagnosis and stability rules and must not have other causes of neuropathy or recent conflicting treatments. Vaccinations and contraception rules apply.

Dystonia Coalition Projects-3

The overall mission of the Dystonia Coalition is to develop a better understanding of the dystonias so that we may improve treatment. Presently, there are four related projects; the first three projects are grouped together because they are related. The last project will be open only to selected participants as an option. 1. Natural History (NH) Project: The aim of this observational project is to better characterize the heterogeneity of clinical manifestations among subjects with dystonia, how these manifestations evolve over time, and how they relate to other family members. A fuller understanding of clinical features and especially their evolution over time is an essential prerequisite for testing any potential disease-modifying therapies that could alter the course of the disorder. 2. Objective Measures (OM) Project: The aim of this project is to exploit technological advances for development of objective tools to measure the severity of dystonia. Current diagnostic and severity measures depend almost entirely on subjective clinician-rated or patient-rated scales. New technology could ultimately replace these subjective scales as outcome measures. They could also be used for telemedicine. This study is not interventional, but instead relies on video recordings or motion sensors that can non-invasively detect movements. 3. Biobank (BB) Project: The aim of this project is to develop a resource that expands the existing dystonia DNA biorepository to include other biomaterials. To date, no large multicenter open-access biorepository exists for any type of dystonia. Such a biobank is essential for improving our understanding of the pathogenesis of the dystonias, so that rational therapies can be planned. It also is essential for exploration of biomarkers of disease activity that may provide useful outcome measures in clinical trials, or insights into pathogenesis. This study also is not interventional. 4. Patient-Centered Outcomes (PCO) Project: The aim of this project is to delineate both between-subject and within-subject variations over time in response to the standard of care treatment with Botulinum toxin (BoNT) injections. Typically, injections are required about every 3 months. Therapeutic benefits emerge within the first week and then wear off after 8-16 weeks, creating a cyclical response known as the "yo-yo" effect. The development of any novel "add-on" therapeutics or replacement therapeutic is hampered by incomplete knowledge of individual temporal responses. Currently, measurement tools rely on clinical rating scales which are subjective, cumbersome for repeated frequent use, and require extensive expertise to apply. This project will develop a patient-facing tool on a hand-held electronic device, such as a smartphone. This is not an interventional study; it aims to collect data regarding responses to routine clinical treatments.

Early Stroke Recovery Biomarkers

This study will test whether simple, early medical tests can predict how well a person's arm recovers after an ischemic stroke. Many people have lasting arm weakness after a stroke. Doctors want reliable markers to tell which patients will do well and which will not. VERIFY will enroll people shortly after an ischemic stroke and collect three types of information: clinical exams of arm strength and function, brain stimulation tests (TMS) that check motor pathways, and MRI brain scans that measure injury to the main motor pathway. The study will follow participants for 90 days and measure arm impairment, arm function, and how much the arm is used in daily life. The goals are to validate that TMS and MRI measures taken early predict 90-day arm outcomes and to test a prediction tool called PREP2 in many centers. About 650 participants across up to 45 sites are planned. The results aim to help select the right patients for future recovery trials and to guide early rehabilitation decisions.

Evaluating brain injury from subdural hematomas using advanced imaging

We hope to conduct advanced MRIs on patients. We think these MRIs will help better understand how subdural hematomas injure the brain and keep people from fully recovering once the blood goes away.

CSL300 for cardiovascular outcomes ESKD

NOT YET OPEN TO RECRUITMENT Study Aims to assess the efficacy of CSL300 on CV outcomes and safety in subjects with ASCVD or diabetes mellitus and evidence of systemic inflammation who are undergoing maintenance dialysis. Medication is an IL-6 MAb. Dialysis patient will receive drug or placebo every 4weeks at dialysis clinic. Outcomes study expected to last 5 years.

StrokeNet Thrombectomy Platform

STEP is a large, multi-center study testing ways to improve care for people who have an acute ischemic stroke caused by a blockage in a large or medium brain artery. The trial runs at many stroke centers and is set up so new treatments can be added over time. It studies several types of approaches: broadening who might get endovascular thrombectomy (a clot-removal procedure), testing new devices used during clot removal, testing medicines given along with the procedure, and testing early or pre-hospital tools and systems to speed care. People are randomly assigned to treatments so researchers can compare results. The main goal is to see which options help people have less disability 90 days after their stroke, while watching for harms like bleeding or death. The study adapts as results come in, so it can stop or expand parts that look better or worse.

Testing Drug Delivery to the Inner Ear

Adults undergoing ear surgery may allow discarded tissue to be studied in the lab to improve future drug delivery to the ear.

Studying Shoulder Replacement Outcomes Using a Custom Baseplate for Severe Glenoid Bone Loss

This study looks at how well people do after a reverse shoulder replacement when they have severe bone loss in the socket of the shoulder (the glenoid). In these cases, a standard implant may not fit securely, so surgeons use a custom‑designed baseplate created from each patient's CT scan. The goal is to better understand early recovery, function, and implant stability in patients who receive these individualized implants. Patients who had this surgery between 2021 and 2024 and are willing to participate will be included. The study collects information from past medical records and from a new clinic visit. During this visit, patients complete short questionnaires about shoulder function and pain and undergo a routine exam that measures how far the shoulder can move. Patients also receive a CT scan so researchers can check how stable the baseplate is and whether screws or components have shifted. All surgeries were already completed as part of normal medical care. The study does not involve any new procedures, additional surgery, or experimental treatments. The custom baseplates used were designed from CT imaging to match each patient's anatomy and were implanted by a shoulder specialist. The information gathered will help surgeons understand how well these custom implants perform in the first months after surgery and whether they offer advantages for people with major glenoid bone loss. Findings may guide future treatment decisions and improve the quality of care for shoulder replacement patients with complex anatomy.

How Operating Table Positioning Affects Spine Alignment During Surgery

When patients have spine surgery, they are placed face‑down on special pads that support the chest and pelvis. Small changes in where these pads are positioned may affect the curve and alignment of the spine during surgery. This study aims to find out how much those pad positions matter. Adults having spine surgery with Dr. Zhang may be invited to join. After anesthesia and before surgery begins, three X‑rays of the lower spine and pelvis are taken: one with the pads in the normal position used for surgery, one with the pads shifted slightly upward, and one with the pads shifted slightly downward. Only the normal X‑ray is part of routine care; the other two are performed for the study. After the images are taken, the pads are returned to the normal position and surgery proceeds as planned. Researchers will measure angles in the spine from each X‑ray to see how the position of the pads affects alignment. The goal is to understand whether certain pad placements change the spine's curve and whether these changes could impact surgical planning or outcomes. The study does not change the surgery itself and involves only minimal extra time and two additional X‑rays. All other aspects of care are standard. The information gathered may help surgeons position patients more precisely in the future and improve alignment during spine surgery.

STRATEGY FOR IMPROVING STROKE TRMT RESP

SISTER is a Phase-2, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.

Bringing Efficiency to the Early Alzheimer's Disease Diagnosis

This study is testing a new way to help doctors identify memory and thinking changes earlier. Adults age 50 and older who report concerns about memory or behavior may complete simple digital thinking tests at home and in the clinic, along with a blood test that looks for signs of Alzheimer's disease. The goal is to see whether this new approach helps people get a diagnosis faster and more accurately. Participants meet with a brain health team, complete questionnaires and thinking tasks, and then receive results from a trained primary care provider.

Ublituximab Modified Regimen Study

This Phase 3b study tests a changed dosing plan of ublituximab, a medicine that targets B cells, in people with relapsing multiple sclerosis (RMS). The study has three parts: Part A is open to eligible participants and looks at MRI brain lesions over about 48 weeks; Part B is randomized and double-blind to study drug levels and compare to placebo up to 16 weeks; Part C enrolls people who had a suboptimal experience on another anti-CD20 treatment to see how they do on ublituximab. Main goals are to see if the modified schedule prevents new gadolinium-enhancing MRI lesions and to understand the drug's blood levels. Participants have regular visits for dosing, safety checks, and MRI scans. People with active infections, certain immune diseases, prior serious infusion reactions to anti-CD20 drugs, some prior cancer or prior use of specific immunosuppressive drugs are not allowed to join.

Trial for Lumateperone in Teens with Schizophrenia or Bipolar Disorder

This research aims to understand the safety and tolerance of the drug lumateperone in teens aged 10 to 17 who have been diagnosed with either schizophrenia or bipolar disorder. The trial lasts up to 30 weeks, starting with a 2-week screening period, followed by a 26-week period where participants take lumateperone daily. After that, there's a 2-week follow-up to check on safety. The main goal is to see how safe the drug is by monitoring any adverse effects that might happen in these patients. Both new participants and patients from previous related studies can join according to their diagnosis and history. Those with other psychiatric disorders, severe risk of self-harm, or dangerous behavior are not eligible.

Understanding Sinus Inflammation

Adults having sinus surgery may provide samples to help researchers understand inflammation and improve treatments.

Afimkibart in Moderate Severe UC

This Phase 3 randomized study tests Afimkibart (RO7790121), an investigational antibody, versus placebo as a short induction treatment for people with moderately to severely active ulcerative colitis. The main goal is to see how many participants reach clinical remission at Week 12 and to measure healing of the colon with endoscopy and tissue tests. The study also looks at early symptom change (Week 2), pain, urgency, fatigue, quality of life, and safety up to about 30 weeks. Eligible adults must weigh at least 40 kg, be up to date on cancer screening, and have tried but not benefited from at least one standard UC therapy. People with certain infections, recent cancers, specific types of colitis, pregnancy, or prior anti‑TL1A treatment are not allowed to join.

Lenacapavir plus bNAbs Versus Cabotegravir

This phase 3, randomized open label study compares two long acting injectable options for adults with HIV whose virus is already controlled on daily oral therapy. One group will switch to a twice yearly regimen of lenacapavir plus two broadly neutralizing antibodies teropavimab and zinlirvimab. The other group will switch to injections of cabotegravir and rilpivirine given every 8 weeks. The main goal is to see if the new lenacapavir plus antibody combination can keep the virus suppressed just as well as the cabotegravir rilpivirine regimen after one year. Participants must have had undetectable viral load before joining and lab tests must show the virus is susceptible to the study antibodies. The study will track viral levels at 52 weeks (primary) and later timepoints, CD4 cell counts, safety and side effects, drug levels in the blood, and whether participants develop antibodies against the study drugs. Follow up goes beyond one year so longer term safety and effectiveness can be assessed.

Beat AML Biomarker Treatment Trial

This study is a master protocol that screens people with acute myeloid leukemia (AML) using rapid lab and genomic testing. Based on the test results, each person is placed into one of several smaller treatment studies that test targeted, investigational therapies or drug combinations. The goal is to complete testing and assign patients to a matched treatment within 7 days, and then follow treatment responses and safety over time. The trial includes groups for newly diagnosed patients, relapsed or refractory patients, and a marker-negative group for those who don't match a specific marker. Some sub-studies focus on older adults or patients who cannot or choose not to get intensive chemotherapy. Follow-up can continue for years to track responses and changes in disease over time.

This study may be appropriate for those with: Newly Diagnosed Cancer

Ubrogepant for Pediatric Migraine

This study tests an oral medicine called ubrogepant to treat a single migraine attack in children and teens aged 6 to 17. The goal is to see if the medicine works and is safe. There are two groups: a PK group (younger children) to help pick the right dose, and the main study. In the main study, participants are randomly given a low dose, a high dose, or a placebo (about a 1 in 3 chance of placebo). If their headache is still moderate or severe after at least 2 hours, they may take a second dose or a rescue medicine. The main measure is how many participants have no headache pain 2 hours after the first dose. Other measures look at symptom relief, staying pain-free up to 24 hours, use of rescue medicine, and side effects. About 1,059 participants will join at many sites across the United States. The study lasts up to 6 months and includes visits for screening, treatment, and follow-up. Doctors will check health, lab tests, ECGs, and ask about any side effects or mood concerns during the study.

Phase 2 Study of ACR-368 in Endometrial Cancer

This Phase 2 study tests ACR-368 in people with high-grade endometrial cancer. Participants are placed into one of three groups. Arms 1 and 2 use a lab test called OncoSignature to predict sensitivity to ACR-368: Arm 1 (OncoSignature Positive) receives ACR-368 alone; Arm 2 (OncoSignature Negative) receives ACR-368 plus ultra-low dose gemcitabine (ULDG). Arm 3 (no OncoSignature testing) also receives ACR-368 with ULDG; EU sites enroll only to Arm 3. Treatment continues until the cancer gets worse, side effects become unacceptable, or the person stops. The main goal is to measure tumor response by CT or MRI every 8 weeks for up to 2 years. Safety, some drug levels in blood, overall survival, time without cancer growth, and duration of any response are also tracked. Key eligibility includes prior platinum chemotherapy and prior anti-PD-(L)1 therapy, measurable disease, and adequate overall health. Certain conditions like uncontrolled viral infections, serious heart disease, recent major surgery or recent cancer treatment, symptomatic brain metastases on high-dose steroids, bowel obstruction, or prior CHK1 inhibitor use will exclude people from joining.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Emergency Contraceptive Metabolism Study

This study looks at why emergency birth control pills sometimes fail for some people and not others. The researchers will give participants a single dose of ulipristal acetate (UPA), the oral emergency contraceptive, and then watch how the body responds. They will use blood tests to measure UPA levels and ultrasound to see whether the ovary releases an egg (ovulation). The main question is whether genetic differences that affect the enzymes that break down UPA change how much drug is in the blood and whether the drug can stop or delay ovulation. Participants will be healthy people aged 18 to 40 with regular, ovulatory menstrual cycles. The study follows one menstrual cycle (about 30 days) and includes screening, the study dose, blood draws, and ultrasound checks. The goal is to better understand who is more likely to have emergency contraceptive failure and to help make emergency contraception work better for everyone.

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

This study may be appropriate for those with: Newly Diagnosed Cancer

Testing a One-Time Gene Therapy for Huntington's Disease

This research is studying a new gene therapy for adults with Huntington's disease. The treatment is given once, during brain surgery, into two areas that are affected by the disease. The goal is to learn if the therapy is safe and whether it can slow down symptoms and help people stay independent longer. Some participants will receive the gene therapy right away, and others will have a sham surgery and may receive the therapy later. Participants will have regular checkups, brain scans, thinking and movement tests, and will use a smartphone and a wrist sensor to track daily activity. Follow-up lasts several years to monitor health and any benefits or side effects. Eligibility includes adults aged 25 to 65 with confirmed Huntington's disease.

Blood Test for Traumatic Brain Injury

This study will enroll adults who come to the emergency department after a head injury and have a head CT scan as part of their care. The research has two parts: one aims to develop a blood test that helps diagnose TBI and predict recovery, and the other follows hospitalized patients to see if blood markers can detect new or worsening brain problems while in hospital. Participants will have blood samples taken early after injury and be followed with clinical checks, imaging done for care (CT or MRI), and outcome assessments at about 2, 14, 28, and 90 days. The study will compare blood marker results with imaging, clinical judgment, and standard outcome scales to find whether the blood test can accurately identify injury, predict recovery, and spot secondary events.

Comparing two ways to track red blood cells after a self-donation transfusion

This research looks at a safer, non-radioactive way to track red blood cells after a person donates and receives back a very small amount of their own cells. Volunteers will donate red cells that are stored for 42 days. A small mixed sample is labeled and given back through a vein so we can see how well the cells recover at 24 hours and how long they stay in the body. We compare a vitamin-based label (biotin) to a traditional radioactive label to learn if the vitamin method works as well. Participants will have regular blood draws and safety checks for about 5 months after the small reinfusion. The information could help future blood products be tested without using radioactivity.

(IV) loading dose , followed 1 week later by DNTH103 (300 mg) administered subcutaneously (SC) every 2 weeks

This is a Phase 3 clinical trial testing DNTH103 in adults with CIDP. The study starts with an open treatment period (Part A, up to 13 weeks) where all participants receive DNTH103. People who respond in Part A may move into a randomized, double-blind, placebo-controlled period (Part B, up to 52 weeks) where they get either DNTH103 or placebo and neither they nor the study team know which. There is an optional open-label extension (OLE) of up to 104 weeks for eligible participants, plus a 40-week safety follow-up. The main goal is to see how long it takes for participants to relapse on study treatment, using standard disability and strength measures. The study also tracks other measures of disability, grip strength, fatigue, quality of life, drug levels in the blood, immune responses to the drug, and any side effects. Vaccination against certain bacteria is required before joining. The study seeks adults who meet set stability and disability scores and who meet treatment history criteria (including those currently treated with standard therapies, those who failed them, or those never treated).

Continuous Passive Motion After Fixation

This study will test whether using a continuous passive motion (CPM) machine after surgery helps control pain and reduce narcotic use in people who had surgery to fix certain pelvis or knee fractures. Adults with an isolated acetabular fracture, supracondylar femur fracture, or tibial plateau fracture who have had surgery will be asked to join. Participants are randomized to either a CPM plus usual physical therapy or usual care with physical therapy alone. The CPM is started after surgery and used while the patient is awake in bed for two hours on and two hours off when not working with physical therapy. Nurses and therapists will record daily pain scores and track pain medications during the hospital stay. Incisions will be checked daily and any problems will be monitored. At one year, participants will complete standard functional surveys to compare recovery. Data are recorded in the electronic health record.

Understanding Chronic Sinusitis Symptoms

This study interviews adults with chronic sinus problems to understand how they recognize flare-ups and symptom control. The goal is to improve future symptom tracking and care.

Using Voice Recordings to Measure Lung Function

This research is studying whether simple voice recordings, like counting out loud or holding a sound, can help measure lung function. It includes adults with neuromuscular diseases and healthy volunteers. These voice tests may help doctors monitor breathing when standard lung tests are difficult or unavailable.

Adolescent Anxiety Treatment Study

This study tests two commonly used antidepressant medicines in adolescents with anxiety to learn who benefits most and who stays well over time. Teens ages 12 to 17 who have generalized, social, separation anxiety or panic disorder are randomly assigned in a double-blind way to take either duloxetine or escitalopram for an acute treatment period. After the masked treatment phase, participants enter an open long-term follow-up to see who maintains improvement or has a relapse and to study which factors predict new depressive disorders. Researchers will measure anxiety symptoms and overall clinical severity at set times. The study requires a caregiver to help monitor safety, confirms health with exams and tests (including pregnancy and urine drug screen), and excludes teens with recent serious suicide risk, significant medical problems, recent substance use disorders, or unstable psychotherapy. The goal is to better match treatments to adolescents and to understand long-term outcomes.

Testing LY3962673 in KRAS G12D-Mutant Solid Tumors

This study is examining a new drug, LY3962673, which aims to treat certain types of advanced cancer that have a specific mutation known as KRAS G12D. These cancers include pancreatic, lung, and colorectal cancers. The study is testing how safe LY3962673 is when used alone and in combination with other chemotherapy drugs, as well as how well it works in reducing tumor size. It will last about five years, and participants will undergo various assessments to track their response to the treatment. The study hopes to determine both the best way to use the drug and its effectiveness over time. Participants who previously had treatments that didn't fully work for these specific cancers might qualify.

This study may be appropriate for those with: Metastatic Cancer

Investigating NBTXR3 and Radiation for Head and Neck Cancer

This study is testing a treatment called NBTXR3 to see how well it works when combined with radiation therapy, compared to just using radiation therapy with or without a drug called cetuximab. The research is focused on elderly patients who have advanced head and neck squamous cell cancer but cannot undergo platinum-based chemotherapy. Participants will be randomly assigned to two groups; one will receive NBTXR3 with radiation therapy, and the other will receive radiation therapy alone or with cetuximab as chosen by their doctor. The goal is to track how long patients live without their cancer getting worse and overall survival, among other measures. The treatment happens over 7 weeks, with a series of follow-up visits planned afterward.

This study may be appropriate for those with: Metastatic Cancer

Testing Comfort of a New Breathing Device

Adults will try a new breathing support device and report comfort and breathing experience. Results may help improve device design.

Endovascular Treatment in Disabled Stroke

This is a prospective, observational study at multiple stroke centers to compare two commonly used care approaches for people who had moderate-to-severe disability before getting a large-vessel ischemic stroke. One approach is standard medical care (medications, blood pressure and cholesterol control, rehab and other supportive measures) and the other adds endovascular thrombectomy (mechanical removal of the clot). The study will enroll adults with pre-stroke disability (moderate to severe) who arrive within 24 hours of stroke symptoms and have a large artery blockage on brain imaging. The main goal is to compare how patients do at about 90 days after treatment-measuring functional outcome, return to prior level, quality of life, and safety (including death and bleeding in the brain). Results aim to guide care decisions for stroke patients who already had disabilities before their stroke.

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

This clinical trial examines the effectiveness and safety of a new drug, UGN-104, for patients with low-grade upper tract urothelial cancer. During the study, UGN-104 is administered directly into the upper urinary tract once a week for six weeks. Patients who show no signs of cancer after these treatments will have follow-up visits and may continue receiving monthly doses as a maintenance treatment plan for up to one year. These maintenance visits help ensure that the cancer does not return. The study involves regular check-ups every three months and lasts up to 15 months. Participants must have been diagnosed with this type of cancer and should not have received certain other treatments or have specific health conditions.

This study may be appropriate for those with: Recurrent Cancer

Understanding Patient Outcomes and Recovery After Shoulder Injuries Treated at UC Orthopaedics

This study is designed to help doctors better understand how people recover from shoulder injuries and what factors influence long‑term outcomes. Researchers will look at past medical records of patients who were treated for shoulder injuries at UC Orthopaedics, whether they had surgery or were treated without an operation. Information such as age, type of injury, treatment received, and follow‑up care will be reviewed to learn more about how different patients recover. Patients will also be asked to complete short surveys that describe their pain levels, shoulder function, and how their injury affects their daily life. These surveys are widely used in orthopedics to understand a patient's overall well‑being and recovery progress. Completion can be done from home using a phone or computer. In addition, patients will have the option to return to clinic for a free shoulder exam performed by an orthopedic provider. This physical exam helps measure strength, movement, and overall shoulder function, giving researchers a more complete picture of recovery. By combining information from medical records, patient surveys, and optional physical exams, this study aims to identify trends in recovery and help doctors provide better care for future patients with shoulder injuries.

Precision Ventilation for ARDS

This is a Phase 3 randomized trial testing whether a personalized way of setting the ventilator can save more lives for patients with moderate to severe ARDS. Patients are randomly assigned to one of two approaches while on a breathing machine. The experimental arm uses an esophageal catheter to measure pressures inside the chest and guides ventilator settings to keep lung stress in a normal range. The control arm receives guided usual care with standard low tidal volume ventilation; esophageal pressure readings are recorded but not shown to the care team. The main measure is death from any cause within 60 days. The study will also look at 28‑day death, time alive and free from the ventilator, need for advanced respiratory support, lung injury markers in blood, breathing complications such as pneumothorax, blood pressure stability, organ function scores, and ICU and hospital length of stay. The goal is to see if precision ventilation reduces lung injury and improves recovery without causing extra harm.

Videofluoroscopic Swallowing Norms

This study will use videofluoroscopy (a moving X-ray of swallowing) to measure how people of different ages swallow. The team will test about 280 healthy adults across the adult age span and will also collect data from three clinical groups at risk for swallowing problems: people with Parkinson disease, people with COPD, and people recently having had a stroke. The goal is to build clear normal ranges for swallowing measures (like airway protection, residue left after swallowing, timing of airway closure, and how well the throat squeezes) and to find practical cutoff points that help tell normal from disordered swallowing. The results aim to help clinicians interpret swallowing tests more reliably and guide diagnosis and treatment decisions.

Beat AML Biomarker Treatment Trial

This study is a master protocol that screens people with acute myeloid leukemia (AML) using rapid lab and genomic testing. Based on the test results, each person is placed into one of several smaller treatment studies that test targeted, investigational therapies or drug combinations. The goal is to complete testing and assign patients to a matched treatment within 7 days, and then follow treatment responses and safety over time. The trial includes groups for newly diagnosed patients, relapsed or refractory patients, and a marker-negative group for those who don't match a specific marker. Some sub-studies focus on older adults or patients who cannot or choose not to get intensive chemotherapy. Follow-up can continue for years to track responses and changes in disease over time.

This study may be appropriate for those with: Newly Diagnosed Cancer

Tasimelteon for Pediatric Insomnia

This is a multicenter, double-blind, randomized Phase 3 study testing a once-daily oral dose of tasimelteon against a matching placebo in children and teens (ages 2 to 17) with insomnia disorder. Participants will be randomly assigned to tasimelteon or placebo and treated for about 12 weeks. The study looks at time to fall asleep and other sleep measures recorded in sleep diaries and with actigraphy, plus daytime functioning and behavior via questionnaires. Safety and tolerability will be monitored by recording any adverse events.

Family Genetic Communication Study

This study tests two ways of letting close family members know about inherited genetic changes found in people newly diagnosed with colorectal cancer. First, patients (called probands) get blood testing for inherited cancer genes. If a harmful inherited change is found, the patient and their eligible first-degree relatives are put into one of two groups. In the usual approach, the patient tells relatives about the test result (proband-mediated). In the other approach, a healthcare team member contacts relatives directly to offer testing and information (provider-mediated). The main goal is to see which method leads to more relatives getting genetic testing within 6 months. The study also looks at whether relatives who test positive take prevention steps within a year, whether testing differs by patient subgroups (such as age, race, or rural vs. urban), the range of inherited variants found, and patient disease-free survival over 3 years. Probands are followed up for up to 3 years; relatives are followed for up to 1 year. Materials and counseling are provided in English or Spanish.

Understanding genetic Parkinson's disease

This study looks at people with a rare genetic form of Parkinson's disease and their family members. Researchers collect samples like blood, spinal fluid, and skin to better understand how the disease develops. The goal is to improve understanding of Parkinson's disease causes.

KarXT for Teen Schizophrenia

This is a randomized, double-blind, placebo-controlled Phase 3 study testing KarXT in adolescents (13–17 years) with schizophrenia. After screening and confirmation of diagnosis, participants are randomly assigned to receive KarXT or placebo. The main goal is to see if KarXT reduces psychotic symptoms compared with placebo after about five weeks of treatment. Safety and overall clinical improvement will also be measured. The study checks symptom scales and global functioning during the treatment period. People with other major psychiatric disorders, significant medical or neurological conditions, known intellectual disability, severe liver problems, or very high blood pressure are not eligible.

REAL AF - Catheter Ablation for Treating Atrial Fibrillation

This study looks into how catheter ablation works for treating people who have Paroxysmal or Persistent Atrial Fibrillation. By observing patients, the research team will gather data on how well these technologies help with atrial fibrillation over time, both in terms of effectiveness and safety. During the study, participants will have regular assessments before and after their catheter ablation procedures. The expected benefits are to determine how good these methods are at stopping irregular heart rhythms and ensuring patient safety.

Study of BNT327 and Chemotherapy for Lung Cancer Treatment

This study is exploring a new drug, BNT327, combined with chemotherapy to treat people with advanced non-small cell lung cancer (NSCLC). The study has two parts (Phase 2 and Phase 3) that compare different doses of BNT327 to find the best option. Participants are split into groups based on the type of lung cancer they have. The study will look at how safe the treatments are and if they work better than current options. It's a global trial where researchers want to see if using BNT327 can improve survival rates and reduce tumor size better than just using chemotherapy alone. It's ongoing, so more participants who fit the requirements are being recruited.

This study may be appropriate for those with: Metastatic Cancer

Long-Term Study of People Living with Bipolar Disorder

This study is following adults who have bipolar disorder over several years to better understand how their moods, health, and daily life change over time. Participants take part in interviews, surveys, memory and thinking tests, and brain scans, and may wear a Fitbit or use a phone app to track sleep and activity. The goal is to learn why bipolar disorder affects people differently so future care can be more personalized and effective.

Lumateperone Pediatric Bipolar Study

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study testing lumateperone in children and adolescents aged 10-17 who have bipolar I or II disorder and are currently in a major depressive episode without psychosis. After a screening period (up to 2 weeks) to confirm eligibility, participants are randomly assigned 1:1 to receive either lumateperone or placebo for 6 weeks while neither participants nor study staff know which treatment is given. About one week after the last dose, patients return for a safety follow-up visit. The main goal is to see if lumateperone improves depressive symptoms at week 6 (measured by a standard depression rating scale) and to monitor safety. Key eligibility points include a confirmed bipolar diagnosis, a recent depressive episode of at least 4 weeks, a history of at least one manic or hypomanic episode, and no high suicide risk or recent manic hospitalization.

Hypotension in PDD and DLB

Is hypotension the mechanism behind cognitive fluctuations in Parkinson's disease dementia and dementia with Lewy Bodies? The aim of the study is tp determine if the cortical electroencephalographic signatures of cognitive fluctuations are present in PDD and DLB patients with OH. We will use a tilt table test to determine if PDD/DLB patients with OH may have a differential electroencephalographic pattern than those without OH. Hypothesis: PDD and DLB patients with OH will have dominant frequency variability between alpha (8.0-12.0 Hz) and pre-alpha (5.5-7.5 Hz) bands compared with patients without OH.

Testing Abemaciclib with 5-Fluorouracil for Metastatic Colorectal Cancer

This clinical trial is investigating how well two drugs, Abemaciclib and 5-Fluorouracil (5-FU), work together in treating people with colorectal cancer that has spread to other parts of the body and hasn't responded to other treatments. The study aims to discover the safest dose of the drug combination that patients can handle without severe side effects. Participants will take Abemaciclib by mouth twice daily, and receive 5-FU through a vein on specific days during each 28-day cycle. Throughout the study, various samples will be collected to track the effectiveness and side effects of the treatment. After finishing the treatment cycles, participants will be monitored every three months for follow-up. Researchers hope this combination will provide a new option for those with this difficult-to-treat cancer type.

This study may be appropriate for those with: Metastatic Cancer

Evaluating Nipocalimab for Reducing Risk of Severe HDFN in Pregnancies

This study aims to determine the effectiveness of a drug called nipocalimab in pregnant women who are at risk for severe Hemolytic Disease of the Fetus and Newborn (HDFN), a condition where the mother's antibodies attack the baby's red blood cells, leading to anemia in the baby. Anemia can cause serious problems for unborn babies, including death. The study compares nipocalimab to a placebo to see if it can safely reduce these risks and improve outcomes like preventing fetal loss or life-threatening conditions. Participants will be randomly assigned to receive either the drug or a placebo and will be monitored throughout their pregnancies and after their babies are born until they are at least 24 weeks old.

ABBV 932 Added to Antidepressants

This is a Phase 2 study testing ABBV-932, an experimental oral medicine, when added to a person's current antidepressant for treating generalized anxiety disorder (GAD) in adults who have not gotten enough benefit from their antidepressant. About 315 adults will be randomly assigned to receive ABBV-932 or a matching placebo along with their current antidepressant. Treatment lasts 6 weeks and participants are followed for 4 more weeks, for about 10 weeks total. Doctors will check for safety by recording side effects and doing medical tests and blood tests. They will measure anxiety and worry with standard questionnaires and clinician ratings to see if ABBV-932 helps reduce symptoms more than placebo.

Testing Radiation Plus Immunotherapy for Metastatic Renal Cell Cancer

This clinical trial is testing whether adding a special type of radiation therapy called stereotactic ablative radiation therapy (SABR) to the usual treatment of immunotherapy can help patients with renal cell cancer that is metastatic, meaning it has spread to other parts, or cannot be surgically removed. Patients are divided into two groups. One group receives only immunotherapy, while the other group gets both SABR and immunotherapy. The hope is that using both SABR and immunotherapy could shrink tumors or stop them from growing. By doing this, doctors aim to see if fewer surgeries are needed and if the time without cancer worsening can be extended. The study will also look at safety and possible side effects such as immune system reactions.

This study may be appropriate for those with: Metastatic Cancer

One Stop Cervical Screening System

This study will test a new, low‑cost system that uses urine spectroscopy and artificial intelligence (AI) on cervical photos to screen and triage women for cervical cancer in Zimbabwe. The project has two parts. In Part 1 (about 2 years) researchers will collect urine and self‑collected vaginal samples from about 1,100 women to improve the urine spectroscopy AI and compare its results to a standard HPV test. They will also collect more cervical images to improve the image‑reading AI and teach it to recognize the transformation zone type. In Part 2 (about 3 years) around 2,100 women will be screened with the AI urine test and a validated HPV test. Women who test positive will have colposcopy, cervical imaging, and biopsy if needed. The study will measure how well the AI urine test and the AI image triage detect histology‑confirmed CIN2+ (high grade precancer or cancer) compared with standard tests, and will check how well AI determines the transformation zone type. The team will also compare costs versus current local practice. Most participants will have one screening visit. HPV‑positive women will return for colposcopy, biopsy, and treatment if required. The study is carried out by IARC with partners in Zimbabwe and other institutions.

BHV7000 for Focal Epilepsy Study

This is a randomized, placebo-controlled trial testing BHV-7000 in adults with focal onset epilepsy that has not been controlled by prior medicines. The study has two parts. In Part A participants are randomly assigned to 25 mg, 50 mg of BHV-7000, or placebo. After Part A, Part B will begin and will randomly assign participants to 75 mg BHV-7000 or placebo. Participants continue their usual anti-seizure medicines and record seizures during an 8-week observation phase, then receive 12 weeks of double-blind treatment. The main goal is to see whether BHV-7000 reduces 28-day average seizure frequency compared with baseline and to measure safety by tracking adverse events and lab abnormalities. Other goals include responder rates (50% and 75% seizure reduction), seizure freedom, early treatment effects (first week and first month), and patient global impression of change.

Immune profiling of kidney transplant rejection

Researchers are studying why kidney transplant rejection occurs by analyzing blood, urine, and kidney biopsy samples collected during standard clinical care. The goal is to better understand immune activity during rejection and support future improvements in transplant treatment. Participation does not involve experimental treatment.

Effect of a Virtual Reality Cognitive Training Intervention for Brain Cancer Survivors

You will either be assigned to a group that uses the virtual reality training system or a group that will complete paper word search puzzles. At the start of the study all participants will be asked to complete three short cognitive tests to check your current memory and thinking skills. You will take the same tests again at the end of the study to see if anything has changed or improved. You will receive a schedule based on your start and end dates that explains which days you will need to complete the study-related tasks. You will complete the tasks at home for 4 weeks, 6 days a week. It will start at 15 minutes a day in week one and increase by 5 minutes each week, ending at 30 minutes a day in week four. You will receive either a VR headset and hand controllers for use with VR-CRT (and portable WI-FI hotspot if you do not have WI-FI at home) or a notebook for use with paper word-search puzzles (WSP). The research study will provide the technology to you free of charge, but with a technology sign-out consent to confirm your agreement to return the VR and WI-FI equipment once the study is completed. If you are in the VR group, you will be trained on how to use the equipment and how to connect the VR equipment to WIFI. Off-the-shelf VR equipment (Meta Quest 3/128 GB with WIFI) will be used.

Frexalimab Versus Teriflunomide in MS

This is a pair of Phase 3, randomized, double-blind studies comparing an investigational antibody called frexalimab to the approved oral drug teriflunomide in adults with relapsing multiple sclerosis (ages 18-55). Each study measures how often participants have relapses over the study period (annualized relapse rate) and follows safety, disability changes, MRI lesion counts, brain volume, cognitive tests, and blood markers. The studies are event-driven: every participant will be treated at least 12 months, and many will be followed up to about 156 weeks (three years). Visits are every 4 weeks for the first 6 months, then every 3 months, with an end-of-study visit and three follow-up visits. Safety monitoring includes tracking adverse events, lab tests, ECGs, and antibodies to the drug. The goal is to see if frexalimab reduces relapses and is safe compared with teriflunomide.

OLZ SAM Pediatric Long Term Safety

This is an extension study for children and adolescents who finished or left earlier ALKS 3831 trials. It will give OLZ/SAM (a combination of olanzapine and samidorphan) to patients with schizophrenia or Bipolar I disorder to see how safe and tolerable the medicine is over the long term. Eligible participants must have completed or recently left the prior study, be suitable for outpatient care, have family support, and agree to birth control rules. The main measure is how often adverse events occur over up to 52 weeks of treatment. People with current suicide risk, certain medical problems, prohibited medications, a positive opioid test, or pregnancy are not allowed to join.

Sac TMT Maintenance in Ovarian Cancer

This late-stage (Phase 3) study is testing a new maintenance option for people with newly diagnosed advanced ovarian cancer whose tumors are HRD-negative. Participants will have already had surgery and first-line platinum-based chemotherapy and shown no disease growth or some response. The study compares sacituzumab tirumotecan (an antibody-drug therapy) given as maintenance, with or without the targeted drug bevacizumab, to the usual standard care (which may include observation or bevacizumab maintenance). The main goal is to find out if the study treatment keeps cancer from getting worse for longer. Researchers will also track overall survival, later disease progression after new treatments, safety and side effects, and quality of life measures using standard questionnaires. Participants will have regular clinic visits for treatment, scans, and assessments during the treatment and for long-term follow-up. The full study follow-up can last several years to measure how long benefits and side effects last.

This study may be appropriate for those with: Newly Diagnosed Cancer

Genetics Guided Escitalopram Study

This study will enroll about 132 teens ages 12-17 who have generalized, social, and/or separation anxiety. For 12 weeks, participants are randomly assigned to one of two ways of giving the antidepressant escitalopram: standard dosing or dosing guided by a genetic test that predicts how they process the drug. The goal is to see whether using genetic information leads to better anxiety relief and fewer side effects, especially activation (increased restlessness or irritability). The study compares changes in anxiety scores over 12 weeks and monitors safety and activation. Caregivers help with safety checks and medicine monitoring. The study includes a screening visit, a baseline visit, and regular follow-up visits during the 12-week treatment period.

Pompe Disease Patient Registry

This is a global, prospective registry that follows people with Pompe disease over time. The registry includes those with infantile-onset and late-onset forms, and it accepts both people who are receiving approved Pompe therapies and those who are not receiving treatment. The main goals are to track long-term safety by collecting reports of adverse events, measure real-world effectiveness of treatments, understand impacts on quality of life through patient-reported outcomes, and describe the natural course of untreated Pompe disease. Participants' medical information is collected during routine care visits and at enrollment. People currently enrolled in clinical trials or receiving investigational therapies for Pompe disease are not eligible. The registry is observational, so no experimental treatments are given as part of the study.

Study of IMPT-314 in R/​R Aggressive B-cell NHL

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Two cohorts of participants will be enrolled: 1) CAR T naïve and 2) CAR T experienced. Up to approximately 60 patients (15 per dose level per cohort) will be enrolled in dose finding Phase 1 part of the study, which will determine the recommended phase 2 dose. Phase 2 will enroll up to approximately 40 additional participants (20 per cohort) to evaluate further the safety and efficacy of IMPT-314. IMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days. Individual participants will remain in the active post-treatment period for approximately 2 years. Participants will continue in long-term follow-up for 15 years from treatment.

This study may be appropriate for those with: Relapsed / Refractory Cancer

REACT AF

REACT‑AF is a multicenter, randomized (1:1), open‑label, blinded endpoint (PROBE) phase III trial testing whether a smartwatch‑guided strategy of short, on‑demand direct oral anticoagulant (DOAC) therapy can prevent stroke and death while reducing bleeding compared with standard continuous DOAC therapy. The trial will enroll about 5,350 adults aged 22-85 with paroxysmal or persistent (non‑permanent) atrial fibrillation and a CHA2DS2‑VASc score of 1-4 (men) or 2-4 (women) without prior stroke or TIA, who are already taking a DOAC at screening. Participants are randomized to one of two arms: 1) experimental - an AF‑sensing smartwatch that, when it detects a qualifying AF episode (>1 hour), triggers a prescribed 30‑day course of a DOAC; or 2) control - continued standard daily DOAC therapy. Remote continuous smartwatch monitoring is used for detection and follow‑up. Follow‑up lasts up to 60 months with regular clinic and remote visits per site protocol. The primary objective is to demonstrate non‑inferiority of the smartwatch‑triggered, time‑limited DOAC strategy versus continuous DOAC for a composite primary outcome of ischemic stroke, systemic embolism, and all‑cause mortality. A key secondary objective is to test whether the smartwatch‑triggered strategy is superior in reducing major bleeding events. Additional safety and exploratory endpoints include AF burden, hospitalization, and adherence measures. Patients with valvular/permanent AF, prior stroke/TIA, very high AF burden, need for other permanent anticoagulation indications, severe renal disease, recent AF procedures, implanted rhythm devices affecting management, pregnancy, or other conditions increasing bleeding risk are excluded.

MM120 Generalized Anxiety Disorder

This Phase 3 study will enroll up to 375 adults (ages 18-74) who have a confirmed diagnosis of generalized anxiety disorder and at least moderate symptoms. Participants will be randomly assigned to receive a single oral dose of MM120 or a matching placebo during a 12-week, double-blind treatment period. The main goal is to compare changes in anxiety symptoms between the MM120 and placebo groups using standard anxiety rating scales. After the 12-week blinded period, participants can join a 40-week open-label extension where they may receive MM120 and will be monitored for safety and symptom control. The study will also track other outcomes such as overall clinical improvement, mood, work and daily functioning, quality of life, and sexual functioning, and will record the need for repeat MM120 treatments during the full 52-week study.

Comparing Effectiveness of Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

This phase II study evaluates the effectiveness of mosunetuzumab versus rituximab, the standard treatment, in extending survival for patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Both mosunetuzumab and rituximab are monoclonal antibodies targeting the CD20 protein on B cells and certain cancer cells, potentially enhancing the immune system's ability to destroy cancer cells. The trial aims to determine if mosunetuzumab offers a superior survival benefit compared to rituximab for individuals with NLPHL.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Comparing Two Surgical Options for Stabilizing Metastatic Bone Disease in the Upper Thigh (PERFORM)

The PERFORM study is a major international research trial comparing two ways of treating cancer‑related bone disease in the upper part of the thigh bone (proximal femur). Some patients develop weak or broken bones in this area when cancer spreads to the skeleton, and surgery is often needed to help them walk safely and reduce pain. The study compares two surgical options: Resection and reconstruction - removing the damaged section of bone and replacing it with an implant. Internal fixation - strengthening the bone using plates, screws, or a rod placed inside the bone. Patients who qualify will be randomly assigned to one of the two procedures. Doctors want to know which option helps patients live longer, stay mobile, and spend more days at home during the year after surgery. The study also measures quality of life, physical function, pain levels, and time spent in hospitals or care facilities. About 334 patients from hospitals across Canada, the U.S., and other countries will participate. Everyone will be followed for one year after their surgery, with check‑ins and questionnaires at several time points. All surgeries and follow‑up visits are standard medical care. The goal of PERFORM is to provide strong evidence to guide surgeons on the best treatment for people with metastatic bone disease in the femur. By comparing these two common surgical approaches, the study will help determine which one offers better long‑term outcomes and quality of life for cancer patients.

Nutrition and Lung Function in CF

This study, called STRONG-CF, is being done by the Jaeb Center for Health Research. It focuses on people with Cystic Fibrosis (CF) and looks at their strength, muscle health, nutrition, and lung function. The main goal is to compare different ways to measure body composition, like how much muscle someone has, using a special scan called DXA, which is considered the best tool for this. The researchers want to see how these measurements relate to things like body mass index (BMI), arm muscle size, hand-grip strength, how far someone can walk in six minutes, and several other health indicators. They will also look at how these measurements change over time and how they relate to lung function, especially in people with different levels of lung health. The study will also check if these body measurements can help predict clinical outcomes, like how well someone with CF is doing. The study will recruit two groups of people with CF based on their lung function: those with an FEV1 (a measure of lung function) below 60% and those with an FEV1 of 60% or above. They will match participants by age, gender, race, and severity of their CF gene. There are some rules about who can join. People can't have had organ transplants, started certain new drugs recently, or had severe lung issues needing antibiotics or steroids recently. Also, people with pacemakers can't join a part of the study. The study is currently recruiting participants, and they hope the results will help in future research on nutrition and health in CF patients.

Anticoagulation in ICH Survivors

The Anticoagulation in Intracerebral Hemorrhage Survivors for Stroke and recovery study is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high risk non valvular AF. A total of 700 patients, age 18 or older with a first ever ICH 14-120 days before entry will be randomized in a 1:1 ratio to receive apixaban ( 5 mg tablet twice daily or 2.5 mg tablets twice daily for patients meeting standard dose adjustment requirements) or aspirin (81 mg tablet once daily).

Stroke Cognitive Recovery Study

This is a large, observational study that will enroll about 8,000 people who are hospitalized with a recent stroke and who do not have known dementia. The study looks at how thinking and memory change after stroke and what factors influence recovery. All participants complete a baseline check, blood sample, and short thinking and daily function tests. They have follow up visits in person at about 3 to 6 months and 18 months, and yearly phone check ups up to four years. Some participants join extra tiers that include brain MRI scans and more detailed thinking tests and blood draws. A smaller group gets special PET scans that look for proteins linked to dementia. The study follows people over time to learn which stroke features, imaging findings, blood markers, and other risks lead to more or less cognitive decline.

Vedolizumab Dual Therapy in Crohns

This clinical study tests whether combining two biologic medicines can help adults with moderate to severe Crohn's disease who have not done well on prior advanced treatments. The study has two parts. In Part A, people receive vedolizumab (given into a vein) together with either adalimumab (injected under the skin) or ustekinumab (given into a vein or injected). People who get benefit from this two-drug treatment at Week 26 may move to Part B and receive vedolizumab alone from Week 30 to Week 46. All participants are followed for safety and results for about 76 weeks total (including a safety follow-up after the last dose). The main goals are to measure healing seen on endoscopy and to see how many reach symptom remission, maintain response, stop steroids, and avoid flares. About 100 participants will be enrolled at multiple sites in the United States and Canada.